Welcome to our dedicated page for Glucose Health SEC filings (Ticker: GLUC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Glucose Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Glucose Health's regulatory disclosures and financial reporting.
Glucose Health, Inc. (GLUC) filed a Form D to report a new exempt private offering of equity securities under Rule 506(b) of Regulation D. The company identifies its industry group as manufacturing and reports annual revenue in the $1 to $1,000,000 range.
The notice states that as of the filing, Glucose Health has sold $10,000 of securities in this offering, with an additional $20,000 remaining to be sold. The issuer reports paying $0 in finders' fees in connection with the offering. The first sale in this offering occurred on August 28, 2026.
Glucose Health, Inc., a Delaware corporation based in Bentonville, Arkansas, filed a notice of an exempt private securities offering relying on Rule 506(b) of Regulation D. The company reports revenue in the $1–$1,000,000 range.
The offering consists of investment units, each including one share of common stock and a warrant to purchase one share of common stock over five years at an exercise price of $0.60 per share. The notice shows $60,000 of securities sold, with an additional $60,000 remaining available in the offering, and discloses $0 in finders’ fees.